方法：收集有晶状体眼Verisyse/Artisan虹膜夹持型人工晶状体植入矫治高度近视58例112眼，记录术前； 术后3，6，12mo的裸眼视力、最佳矫正视力、屈光度、角膜内皮细胞计数、眼压的变化。

结果：术后3mo全部患者裸眼视力≥0.5，术后6mo最佳矫正视力≥0.8占72.3%，98%眼残余屈光度与目标屈光度相差±1.00D以内，术后3，6，12mo患者的等值有效球镜、散光度数与术前相比有统计学意义(P<0.05)，眼压与术前相比无统计学意义(P>0.05)，角膜内皮细胞有进行性的丢失，但术后3，6mo的角膜内皮细胞计数与术前相比无统计学意义(P>0.05)。无任何一眼发生青光眼、白内障和角膜内皮的失代偿等严重并发症。

结论：Verisyse/Artisan有晶状体眼虹膜夹持型人工晶状体植入矫治高度近视安全、有效、稳定、可预测性强，术后视觉满意度高，未出现严重的并发症，但远期手术效果还需长期临床观察。

METHODS:Totally 58 cases(112 eyes)of the Verisyse/Artisan iris-fixated phakic intraocular lens for correction of high myopia were collected, the preoperative and 3, 6 and 12 months postoperative examination such as uncorrected visual acuity(UCVA), best-corrected visual acuity(BCVA), refraction, endothelial cell, intraocular pressure were observed.

RESULTS: All of 112 eyes were implanted successfully and were followed-up for 1 year. UCVA of all patients were ≥0.5 three months after surgery, 72.3% of eyes with BCVA ≥0.8 six months after surgery, 98% of eyes residual refraction≤±1.00diopters(D)1 year after surgery. There were significant differences between preoperative and 3, 6 and 12 months postoperative spherical equivalent refraction and astigmatism(P<0.05). There were no significant differences between preoperative and 3 and 6 months postoperative intraocular pressure and counts of endothelial cell(P>0.05), but endothelial cell will be loss with the increase of observation time after surgery. Glaucoma, cataract, corneal endothelial decompensation and other serious complications were not found in our study.

CONCLUSION: Verisyse/Artisan iris-fixated phakic intraocular lens for correction of high myopia is effective, safe and predictable. All patients satisfied with the improvement of visual, no serious complications were found, but further clinical observed for a long period of time is necessary.